Literature DB >> 10342633

Responsiveness of outcome measures in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group.

N Ruperto1, A Ravelli, F Falcini, L Lepore, A Buoncompagni, V Gerloni, M Bardare, E Cortis, F Zulian, M L Sardella, C Giovanni Strano, M Alessio, M G Alpigiani, D Migliavacca, A Pistorio, S Viola, A Martini.   

Abstract

OBJECTIVE: To examine the responsiveness of the disease activity measures more commonly used in juvenile chronic arthritis (JCA) clinical trials.
METHODS: Data were obtained from an open-label, non-controlled, multicentre trial designed to investigate the efficacy of methotrexate (MTX) in children with JCA. Outcome measures, including physician and parent global assessments, functional ability measures, articular variables, and laboratory indicators of systemic inflammation, were assessed at baseline and after 6 months of MTX treatment in 132 patients. Responsiveness of endpoint variables was evaluated by assessing the effect size (ES) and the standardized response median (SRM).
RESULTS: Physician and parent global assessments were the more responsive instruments, showing ES and SRM above 1.0. Erythrocyte sedimentation rate, C-reactive protein, functional status measures and articular variables showed intermediate responsiveness. Morning stiffness, haemoglobin and platelet count were the least responsive instruments.
CONCLUSION: The results of our analysis indicate that subjective estimations of the disease activity, either by the physician or parents, are the most responsive instruments in the assessment of the therapeutic response in children with JCA. The responsiveness of outcome measures in JCA should be further investigated in prospective controlled studies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10342633     DOI: 10.1093/rheumatology/38.2.176

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  8 in total

Review 1.  Outcome measures and medical progress: why outcome measures are needed in childhood arthritis.

Authors:  Francesco Zulian
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

Review 2.  Medical management of children with juvenile rheumatoid arthritis.

Authors:  J T Cassidy
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 3.  Outcome measures in childhood rheumatic diseases.

Authors:  L B Tucker
Journal:  Curr Rheumatol Rep       Date:  2000-08       Impact factor: 4.592

4.  Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis.

Authors:  C Moretti; S Viola; A Pistorio; S Magni-Manzoni; N Ruperto; A Martini; A Ravelli
Journal:  Ann Rheum Dis       Date:  2005-02       Impact factor: 19.103

5.  Myeloid-related protein 8/14 in plasma and serum in patients with new-onset juvenile idiopathic arthritis in real-world setting in a single center.

Authors:  Paula L Keskitalo; Salla M Kangas; Sirja Sard; Tytti Pokka; Virpi Glumoff; Petri Kulmala; Paula Vähäsalo
Journal:  Pediatr Rheumatol Online J       Date:  2022-06-16       Impact factor: 3.413

6.  Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept.

Authors:  M Halbig; G Horneff
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

Review 7.  Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.

Authors:  Tatjana Welzel; Carolyn Winskill; Nancy Zhang; Andreas Woerner; Marc Pfister
Journal:  Pediatr Rheumatol Online J       Date:  2021-03-25       Impact factor: 3.054

8.  Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis.

Authors:  Angelo Ravelli; Alessandro Consolaro; Alessandra Alongi; Gabriella Giancane; Roberta Naddei; Valentina Natoli; Francesca Ridella; Marco Burrone; Silvia Rosina; Gaelle Chedeville; Ekaterina Alexeeva; Gerd Horneff; Ivan Foeldvari; Giovanni Filocamo; Tamàs Constantin; Nicolino Ruperto
Journal:  RMD Open       Date:  2022-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.